Visfatin -948 G/T and resistin -420 C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases

Genome

Volumn 57, Issue 5, 2014, Pages 259-266

  Motawi, Tarek M K ^a   Shaker, Olfat G ^b   El Sawalhi, Maha M ^a   Abdel Nasser, Zeinab M ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c October University for Modern Sciences and Arts   (Egypt)

Author keywords

Cardiovascular disease; NAMPT 948 G T; Polymorphisms; RETN 420 C G; Type 2 diabetes mellitus

Indexed keywords

CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; RESISTIN; RETN PROTEIN, HUMAN;

ADULT; BLOOD; CARDIOVASCULAR DISEASE; CAUCASIAN; COMPLICATION; DISEASE PREDISPOSITION; EGYPT; FEMALE; GENETIC ASSOCIATION; GENETICS; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CARDIOVASCULAR DISEASES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; EGYPT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RESISTIN;

EID: 84909645726     PISSN: 08312796     EISSN: None     Source Type: Journal    
DOI: 10.1139/gen-2014-0022     Document Type: Article

References (56)

1. Antuna-Puente B. Feve B. Fellahi S. Bastard J.-P. 2008. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 34 (1): 2-11. 10.1016/j.diabet.2007.09.004. 18093861.
2. Bailey S.D. Loredo-Osti J.C. Lepage P. Faith J. Fontaine J. Desbiens K.M. et al 2006. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes, 55 (10): 2896-2902. 10.2337/db06-0189. 17003359.
3. Bastard J.P. Maachi M. Lagathu C. Kim M.J. Caron M. Vidal H. et al 2006. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Network, 17 (1): 4-12. 16613757.
4. Böttcher Y. Teupser D. Enigk B. Berndt J. Klöting N. Schön M.R. et al 2006. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J. Clin. Endocrinol. Metab. 91 (7): 2725-2731. 10.1210/jc.2006-0149. 16636125.
5. Chang Y.-H. Chang D.-M. Lin K.-C. Shin S.-J. Lee Y.-J. 2011. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab. Res. Rev. 27 (6): 515-527. 10.1002/dmrr.1201. 21484978.
6. Conneely K.N. Silander K. Scott L.J. Mohlke K.L. Lazaridis K.N. Valle T.T. et al 2004. Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects. Diabetologia, 47 (10): 1782-1788. 10.1007/s00125-004-1537-x. 15517149.
7. El-Mesallamy H.O. Kassem D.H. El-Demerdash E. Amin A.I. 2011. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism, 60 (1): 63-70. 10.1016/j.metabol.2010.04.008.
8. El-Shal A.S. Pasha H.F. Rashad N.M. 2013. Association of resistin gene polymorphisms with insulin resistance in Egyptian obese patients. Gene, 515 (1): 233-238. 10.1016/j.gene.2012.09.136. 23178185.
9. Emamgholipour S. Hossein-Nezhad A. Najmafsha R.A. Rahmani M. Larijani B. 2009. Promoter resistin gene polymorphism in patients with type 2 diabetes and its influence on concerned metabolic phenotypes. Iran. J. Diabetes Lipid Disord. 2009 (8-Dec): 150-156.
10. Fain J.N. Cheema P.S. Bahouth S.W. Lloyd Hiler M. 2003. Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun. 300 (3): 674-678. 10.1016/S0006-291X(02)02864-4. 12507502.
11. Filippatos T.D. Randeva H.S. Derdemezis C.S. Elisaf M.S. Mikhailidis D.P. 2010. Visfatin/PBEF and atherosclerosis-related diseases. Curr. Vasc. Pharmacol. 8 (1): 12-28. 10.2174/157016110790226679. 19485930.
12. Filippatos T.D. Tsimihodimos V. Derdemezis C.S. Gazi I.F. Saougos V. Mikhailidis D.P. et al 2013. Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutr. Metab. Cardiovasc. Dis. 23 (4): 330-336. 10.1016/j.numecd.2011.07.002. 21963513.
13. Fujinami A. Obayashi H. Ohta K. Ichimura T. Nishimura M. Matsui H. et al 2004. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin. Chim. Acta, 339 (1-2): 57-63. 10.1016/j.cccn.2003.09.009. 14687894.
14. Fukuhara A. Matsuda M. Nishizawa M. Segawa K. Tanaka M. Kishimoto K. et al 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307 (5708): 426-430. 10.1126/science.1097243. 15604363.
15. Fukuhara A. Matsuda M. Nishizawa M. Segawa K. Tanaka M. Kishimoto K. et al 2007. Retraction. Science, 318 (5850): 565. 17962537.
16. Gligor R. Zdremtan D. Pilat L. Matei I. Ionescu-Tîrgovişte C. Crînic I. 2012. Correlation of visfatin with the lipidic metabolism in diabetic and obese patients. Proc. Rom. Acad., Series B, 1: 37-43.
17. Goldstein B.J. 2002. Insulin resistance as the core defect in type 2 diabetes mellitus. Am. J. Cardiol. 90 (5A): 3g-10g. 10.1016/S0002-9149(02)02553-5. 12231073.
18. Grundy S.M. Cleeman J.I. Merz C.N. Brewer H.B. Jr. Clark L.T. Hunninghake D.B. et al 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 44 (3): 720-732. 10.1016/j.jacc.2004.07.001. 15358046.
19. Gulcelik N.E. Usman A. Gürlek A. 2009. Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine, 36 (3): 397-403. 10.1007/s12020-009-9234-7. 19779867.
20. Hajer G.R. van Haeften T.W. Visseren F.L. 2008. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 29 (24): 2959-2971. 10.1093/eurheartj/ehn387. 18775919.
21. Hivert M.F. Sullivan L.M. Fox C.S. Nathan D.M. D'Agostino R.B. Sr. Wilson P.W. Meigs J.B. 2008. Associations of adiponectin, resistin, and tumor necrosis factor-α with insulin resistance. J. Clin. Endocrinol. Metab. 93 (8): 3165-3172. 10.1210/jc.2008-0425. 18492747.
22. Hivert M.F. Manning A.K. McAteer J.B. Dupuis J. Fox C.S. Cupples L.A. et al 2009. Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study. Diabetes, 58 (3): 750-756. 10.2337/db08-1339. 19074981.
23. Hussain S. Asghar M. Javed Q. 2010. Resistin gene promoter region polymorphism and the risk of hypertrophic cardiomyopathy in patients. Transl. Res. 155 (3): 142-147. 10.1016/j.trsl.2009.10.002. 20171599.
24. Jamaluddin M.S. Weakley S.M. Yao Q. Chen C. 2012. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br. J. Pharmacol. 165 (3): 622-632. 10.1111/j.1476-5381.2011.01369.x. 21545576.
25. Johansson L.M. Johansson L.E. Ridderstråle M. 2008. The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects. Metabolism, 57 (11): 1558-1562. 10.1016/j.metabol.2008.06.011. 18940394.
26. Körner A. Böttcher Y. Enigk B. Kiess W. Stumvoll M. Kovacs P. 2007. Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. Metabolism, 56 (6): 772-777. 10.1016/j.metabol.2007.01.009. 17512309.
27. Leander K. Gigante B. Silveira A. Vikstrom M. Hamsten A. Hogberg J. 2012. NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction. Clin. Chim. Acta, 413 (7-8): 727-732. 10.1016/j.cca.2012.01.002. 22251423.
28. Lim S. Koo B.K. Cho S.W. Kihara S. Funahashi T. Cho Y.M. et al 2008. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis, 196 (1): 398-404. 10.1016/j.atherosclerosis.2006.11.017. 17178123.
29. Luk T. Malam Z. Marshall J.C. 2008. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J. Leukocyte Biol. 83 (4): 804-816. 10.1189/jlb.0807581. 18252866.
30. Ma X. Warram J.H. Trischitta V. Doria A. 2002. Genetic variants at the resistin locus and risk of type 2 diabetes in Caucasians. J. Clin. Endocrinol. Metab. 87 (9): 4407-4410. 10.1210/jc.2002-020109. 12213908.
31. Matthews D.R. Hosker J.P. Rudenski A.S. Naylor B.A. Treacher D.F. Turner R.C. 1985. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28 (7): 412-419. 10.1007/BF00280883. 3899825.
32. McTernan P.G. Kusminski C.M. Kumar S. 2006. Resistin. Curr. Opin. Lipidol. 17 (2): 170-175. 10.1097/01.mol.0000217899.59820.9a. 16531754.
33. Menzaghi C. Coco A. Salvemini L. Thompson R. De Cosmo S. Doria A. Trischitta V. 2006. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. J. Clin. Endocrinol. Metab. 91 (7): 2792-2795. 10.1210/jc.2005-2715. 16670163.
34. Menzaghi C. Bacci S. Salvemini L. Mendonca C. Palladino G. Fontana A. et al 2013. Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PloS ONE, 8 (6): e64729. 10.1371/journal.pone.0064729. 23755138.
35. Miyamoto Y. Morisaki H. Kokubo Y. Yamanaka I. Tomoike H. Okayama A. et al 2009. Resistin gene variations are associated with the metabolic syndrome in Japanese men. Obes. Res. Clin. Pract. 3: 65-74. 10.1016/j.orcp.2008.11.003. 24345560.
36. Norata G.D. Ongari M. Garlaschelli K. Raselli S. Grigore L. Catapano A.L. 2007. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur. J. Endocrinol. 156 (2): 279-284. 10.1530/eje.1.02338. 17287419.
37. Osawa H. Tabara Y. Kawamoto R. Ohashi J. Ochi M. Onuma H. et al 2007. Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care, 30 (6): 1501-1506. 10.2337/dc06-1936. 17384338.
38. Paschou P. Kukuvitis A. Yavropoulou M.P. Dritsoula A. Giapoutzidis V. Anastasiou O. et al 2010. Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population. Cytokine, 51 (1): 25-27. 10.1016/j.cyto.2010.04.006. 20451405.
39. Romacho T. Sánchez-Ferrer C.F. Peiró C. 2013. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflammation, 2013: 946427. 10.1155/2013/946427. 23843684.
40. Saddi-Rosa P. Oliveira C.S. Giuffrida F.M. Reis A.F. 2010. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol. Metab. Syndr. 2: 21. 10.1186/1758-5996-2-21. 20346149.
41. Saddi-Rosa P. Viana de Oliveira C.S. Crispim F. Giuffrida F.M. de Lima V.C. Vieira J.G. et al 2013. Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects. Cardiovasc. Diabetol. 12 (1): 119. 10.1186/1475-2840-12-119. 23968400.
42. Scherer P.E. 2006. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes, 55 (6): 1537-1545. 10.2337/db06-0263. 16731815.
43. Shaw J.E. Sicree R.A. Zimmet P.Z. 2010. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87 (1): 4-14. 10.1016/j.diabres.2009.10.007. 19896746.
44. Soumaya K. 2012. Molecular mechanisms of insulin resistance in diabetes. Adv. Exp. Med. Biol. 771: 240-251. 10.1007/978-1-4614-5441-0-19. 23393683.
45. Suriyaprom K. Phonrat B. Namjuntra P. Chanchay S. Tungtrongchitr R. 2009. The +299(G>A) resistin gene polymorphism and susceptibility to type 2 diabetes in Thais. J. Clin. Biochem. Nutr. 44 (1): 104-110. 10.3164/jcbn.08-224. 19177195.
46. Tang N.-P. Wang L.-S. Yang L. Zhou B. Gu H.-J. Sun Q.-M. et al 2008. A polymorphism in the resistin gene promoter and the risk of coronary artery disease in a Chinese population. Clin. Endocrinol. 68 (1): 82-87. 10.1111/j.1365-2265.2007.03003.x. 17727677.
47. Tokuyama Y. Osawa H. Ishizuka T. Onuma H. Matsui K. Egashira T. et al 2007. Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus. Metabolism, 56 (5): 693-698. 10.1016/j.metabol.2006.12.019. 17445546.
48. Tsukahara T. Nakashima E. Watarai A. Hamada Y. Naruse K. Kamiya H. et al 2009. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res. Clin. Pract. 84 (2): 179-186. 10.1016/j.diabres.2008.10.021. 19269054.
49. Ukkola O. Kunnari A. Kesaniemi Y.A. 2008. Genetic variants at the resistin locus are associated with the plasma resistin concentration and cardiovascular risk factors. Regul. Peptides, 149 (1-3): 56-59. 10.1016/j.regpep.2007.08.025. 18440081.
50. Uslu S. Kebapci N. Kara M. Bal C. 2012. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp. Ther. Med. 4 (1): 113-120. 10.3892/etm.2012.557. 23060933.
51. Wen Y. Lu P. Dai L. 2013. Association between resistin gene -420 C/G polymorphism and the risk of type 2 diabetes mellitus: a meta-analysis. Acta Diabetol. 50 (2): 267-272. 10.1007/s00592-010-0247-8. 21190046.
52. Xie H. Tang S.-Y. Luo X.-H. Huang J. Cui R.-R. Yuan L.-Q. et al 2007. Insulin-like effects of visfatin on human osteoblasts. Calcif. Tissue Int. 80 (3): 201-210. 10.1007/s00223-006-0155-7. 17340225.
53. Xu J.Y. Sham P.C. Xu A. Tso A.W. Wat N.M. Cheng K.Y. et al 2007. Resistin gene polymorphisms and progression of glycaemia in southern Chinese: a 5-year prospective study. Clin. Endocrinol. 66 (2): 211-217. 10.1111/j.1365-2265.2006.02710.x. 17223990.
54. Yan J.-J. Tang N.-P. Tang J.-J. Jia E.-Z. Wang M.-W. Wang Q.-M. et al 2010. Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population. Clin. Chim. Acta, 411 (1-2): 26-30. 10.1016/j.cca.2009.09.033. 19804767.
55. Zhang L.Q. Heruth D.P. Ye S.Q. 2011. Nicotinamide phosphoribosyltransferase in human diseases. J. Bioanal. Biomed. 3: 13-25. 22140607.
56. Zhang Y.-Y. Gottardo L. Thompson R. Powers C. Nolan D. Duffy J. et al 2006. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity, 14 (12): 2119-2126. 10.1038/oby.2006.247. 17189536.